TREATING DIABETES AND RHEUMATOID ARTHRITIS USING PERSONALIZED MEDICATION

As in the cases of non-communicable but chronic and autoimmune disorders like diabetes, cancer, anemia and rheumatoid arthritis are growing threat to humans. They depend on the genetic information and the genome sequence of the patients and other factors like environmental factors. In most of the cases, the pattern of the disease, i.e. pathogenesis is different for every individual, though phenotypic expression is same. Hence, there is a greater risk for the patient having the genes which are likely to cause above mentioned diseases and side effects or adverse drug reactions due to the therapy available. This occurs due to only one reason that every individual will not react to a drug in a same way. For minimizing these unwanted side effects or adverse reactions which are disease related and for giving patients a better and a bit healthy life, personalizing the medication is essential. This personalization involves the study of phenotypic and genotypic information of the patient and then planning the 3D’s i.e. choice of drug, dose and diet is must. As the diabetic patients worldwide have risen steadily over the past three decades, one of the reasons behind such rise in autoimmune diseases may be the availability of very few specific drugs to treat them. Personalize medication is a hot topic nowadays. In this article we are discussing diabetes and rheumatoid arthritis management by studying the genotype and molecular profile of the patients.